Novo Nordisk (NVO.US) fell 3.3% to $38.48

In terms of news, Novo Nordisk has received a warning letter from the U.S. Food and Drug Administration (FDA) for failing to report all suspected side effects experienced by patients taking the weight-loss drug Ozempic. The FDA pointed out in the letter that the cases included two deaths and one suicide, all involving patients who had received semaglutide treatment, which is the generic name for Ozempic and Wegovy. The FDA did not specify whether these deaths or other side effects were related to the drug. (Gelonghui)